Universal CD19/CD22-targeted CAR-T cells (CTA101) with the TRAC region and CD52 gene disrupted with CRISPR/Cas9 have been administered to patients with relapsed or refractory ALL [109]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.